Welcome to our dedicated page for Lifemd news (Ticker: LFMDP), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
News for LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) is closely tied to developments at LifeMD, Inc., the issuer of this preferred security. LifeMD regularly publishes updates about its virtual primary care and pharmacy operations, financing activities, and corporate governance, all of which can be relevant to investors following LFMDP.
Company announcements describe LifeMD as a provider of virtual primary care services and pharmacy solutions, with telemedicine, laboratory access, and pharmacy services supporting treatment across more than 200 conditions. News items highlight growth in telehealth revenue, expansion into areas such as weight management, women’s health, mental and behavioral health, and cardiometabolic care initiatives, and the evolution of its virtual care platform.
Investors tracking LFMDP can expect news related to LifeMD’s clinical programs, including collaborations with pharmaceutical manufacturers. Recent releases discuss expanded collaboration with Novo Nordisk, access to Wegovy and Ozempic within LifeMD’s weight management program, and the addition of the Wegovy pill to its virtual obesity care offering. Other updates cover developments in women’s health programs, including the appointment of clinical advisors, and the scaling of men’s health and RexMD-branded services.
Corporate and financial news is also significant for LFMDP followers. LifeMD has issued press releases on quarterly financial results, changes in independent registered public accounting firms, the divestiture of its majority interest in WorkSimpli Software LLC to focus on virtual care and pharmacy, and the establishment of a revolving credit facility. The company has additionally announced quarterly cash dividends on the 8.875% Series A Cumulative Perpetual Preferred Stock.
By reviewing the LFMDP news feed, readers can monitor how LifeMD’s virtual care strategy, partnerships, financial decisions, and governance updates may influence the context in which this preferred stock operates. Regular news provides a consolidated view of operational milestones and capital structure developments that matter to preferred and common equity holders alike.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
LifeMD, Inc. (NASDAQ: LFMD) has launched new membership plans aimed at enhancing access to virtual primary care services. The innovative features in the proprietary mobile app now allow consumers to download it for free, gain access to a symptom checker, a discounted prescription card, and a live appointment queue for immediate virtual consultations. The company is introducing three membership tiers: FlexCare, which requires no membership fee; TotalCare, a quarterly plan that includes monthly visits; and ConciergeCare, which offers unlimited visits with a dedicated doctor. The expansion of these services is anticipated to support ongoing membership growth and positions LifeMD favorably in the evolving telehealth market, expected to see significant disruption by 2030 according to Bain and Co.
LifeMD, Inc. (NASDAQ: LFMD/LFMDP) announced a cash dividend of $0.5546875 per share on its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP). The dividend will be paid on April 17, 2023, to shareholders on record as of April 7, 2023. This move reflects the company's commitment to providing returns to its preferred shareholders. LifeMD is a telehealth provider that offers a range of virtual healthcare services across the United States, leveraging a proprietary technology platform and nationwide pharmacy network to enhance healthcare accessibility.
LifeMD reported a significant milestone in Q4 2022, achieving consolidated Adjusted EBITDA profitability for the first time, totaling $631,000. Full Year 2022 consolidated revenue reached $119.0 million, a 28% increase year-over-year, despite a $2.9 million impact from deferred telehealth shipments in Q4. The company executed a $40 million debt financing agreement with Avenue Capital, bolstering its capital position for future growth. Guidance for 2023 indicates projected revenue of $140-$150 million and Adjusted EBITDA of $12-$18 million. Notably, active telehealth subscribers grew by 22% to approximately 169,000.
FAQ
What is the current stock price of Lifemd (LFMDP)?
